Novo signs development deal with Swedish biotech Nanexa to license long-acting delivery technology

Novo Nordisk has entered a new development agreement with the Swedish biotech Nanexa.

Under the pact, Nanexa will license its long-acting drug delivery platform to Novo, expanding the larger company's technology options. The announcement did not disclose financial terms or timelines.

While investors had hoped for a larger, transformative partnership, the deal is modest in scale but adds another collaborative element to Novo's pipeline strategy.